268 related articles for article (PubMed ID: 19135330)
1. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia.
Tam VH; Chang KT; Schilling AN; LaRocco MT; Genty LO; Garey KW
Diagn Microbiol Infect Dis; 2009 Mar; 63(3):279-85. PubMed ID: 19135330
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa.
Tam VH; Schilling AN; LaRocco MT; Gentry LO; Lolans K; Quinn JP; Garey KW
Clin Microbiol Infect; 2007 Apr; 13(4):413-8. PubMed ID: 17359326
[TBL] [Abstract][Full Text] [Related]
3. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa.
Tam VH; Chang KT; LaRocco MT; Schilling AN; McCauley SK; Poole K; Garey KW
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):309-14. PubMed ID: 17617302
[TBL] [Abstract][Full Text] [Related]
5. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
6. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
[TBL] [Abstract][Full Text] [Related]
7. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
8. Beta-lactamases identified in clinical isolates of Pseudomonas aeruginosa.
Zhao WH; Hu ZQ
Crit Rev Microbiol; 2010 Aug; 36(3):245-58. PubMed ID: 20482453
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
[TBL] [Abstract][Full Text] [Related]
10. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC
Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
Tuon FF; Gortz LW; Rocha JL
Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
[TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.
Hsu DI; Okamoto MP; Murthy R; Wong-Beringer A
J Antimicrob Chemother; 2005 Apr; 55(4):535-41. PubMed ID: 15728150
[TBL] [Abstract][Full Text] [Related]
13. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.
Marra AR; Pereira CA; Gales AC; Menezes LC; Cal RG; de Souza JM; Edmond MB; Faro C; Wey SB
Antimicrob Agents Chemother; 2006 Jan; 50(1):388-90. PubMed ID: 16377720
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.
Johnson LE; D'Agata EM; Paterson DL; Clarke L; Qureshi ZA; Potoski BA; Peleg AY
Transpl Infect Dis; 2009 Jun; 11(3):227-34. PubMed ID: 19302282
[TBL] [Abstract][Full Text] [Related]
15. Detection of a new extended-spectrum oxacillinase in Pseudomonas aeruginosa.
Fournier D; Hocquet D; Dehecq B; Cholley P; Plésiat P
J Antimicrob Chemother; 2010 Feb; 65(2):364-5. PubMed ID: 20008045
[No Abstract] [Full Text] [Related]
16. Pseudomonas aeruginosa bloodstream infections: how should we treat them?
van Delden C
Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S71-5. PubMed ID: 17698326
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Miyajima Y; Hiramatsu K; Mizukami E; Morinaga R; Ishii H; Shirai R; Kishi K; Tokimatsu I; Saikawa T; Kadota J
Int J Antimicrob Agents; 2008 Nov; 32(5):437-40. PubMed ID: 18715759
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.
Lee CC; Lee CH; Hong MY
Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263
[TBL] [Abstract][Full Text] [Related]
19. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units.
Georges B; Conil JM; Dubouix A; Archambaud M; Bonnet E; Saivin S; Lauwers-Cancès V; Cristini C; Cougot P; Decun JF; Mathe O; Chabanon G; Marty N; Seguin T; Houin G
Crit Care Med; 2006 Jun; 34(6):1636-41. PubMed ID: 16557152
[TBL] [Abstract][Full Text] [Related]
20. Providing β-lactams a helping hand: targeting the AmpC β-lactamase induction pathway.
Mark BL; Vocadlo DJ; Oliver A
Future Microbiol; 2011 Dec; 6(12):1415-27. PubMed ID: 22122439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
